# Assess national strategic plans & national guidelines

Country teams should use this document to assess the core child and adolescent TB elements that the COE recommend being included in national-level guidelines and strategic planning documents.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Thematic area** | **Topics/content**  | **National** **strategic plan**  | **National and/or****child TB guidelines** | **Other document1**  |
| **Child and adolescent TB epidemiology** | TB burden | Child TB case notification rates |[ ] [ ] [ ]
|  |  | Proportion of child TB cases out of overall cases |[ ] [ ] [ ]
|  |  | Adolescent TB case notification rates  |[ ] [ ] [ ]
|  |  | Proportion of adolescent TB cases out of overall cases |[ ] [ ] [ ]
| **Child and adolescent TB performance monitoring** | Targets for child TB diagnosis (e.g., 10% of all case notifications are children) |[ ] [ ] [ ]
|  | Target for TB treatment among children  | TB treatment success (e.g., 95% of all children who initiate treatment complete treatment and/or are documented as cured) |[ ] [ ] [ ]
|  | Targets for TPT among CLHIV  | TPT initiation (e.g., 95% of CLHIV without TB initiate TPT) |[ ] [ ] [ ]
|  |  | TPT completion (e.g., 90% of CLHIV initiated on TPT complete TPT) |[ ] [ ] [ ]
|  | Targets for TPT among child contacts  | TPT initiation (e.g., 95% of child contacts without TB initiate TPT) |[ ] [ ] [ ]
|  |  | TPT completion (e.g., 90% of child contacts initiated on TPT complete TPT) |[ ] [ ] [ ]
|  | Targets for TB among adolescents | Diagnosis |[ ] [ ] [ ]
|  |  | Treatment |[ ] [ ] [ ]
|  |  | Prevention |[ ] [ ] [ ]
|  | Indicators to monitor child TB diagnosis, treatment, and prevention program performance |[ ] [ ] [ ]
|  | Indicators to monitor for adolescent TB diagnosis, treatment, and prevention program performance |[ ] [ ]  [ ]  |
| **Child and adolescent TB data management and forecasting** | TB recording and reporting tools  |[ ] [ ] [ ]
|  | TB data are reported within age bands 0-4 years and 5-14 years | N/A | [ ]  |[ ]
|  | Forecasting stock and commodities for child and adolescent TB diagnosis, treatment, and prevention  | [ ]  | [ ]  |[ ]
| **Child and adolescent TB prevention** | Recommended use of neonatal BCG vaccine in collaboration with EPI and MNCH services | N/A | [ ]  |[ ]
|  | TPT regimens and dosages for children and adolescents  | N/A | [ ]  |[ ]
|  | Monitoring, managing, and reporting adverse events for children and adolescents receiving TPT | N/A | [ ]  |[ ]
|  | Integration of TPT services with family and community-centered strategies  | N/A | [ ]  |[ ]
| **Child and adolescent drug-resistant TB** | Regimens and dosages for children and adolescents diagnosed with DR- TB | N/A | [ ]  |[ ]
| **Child and adolescent TB diagnosis** | Contact investigation | Listing and screening contacts | N/A | [ ]  |[ ]
|  |  | Referral for further investigations | N/A | [ ]  |[ ]
|  |  | Offering TB treatment or TPT | N/A | [ ]  |[ ]
|  |  | Reverse contact investigation (if child is index case) | N/A | [ ]  |[ ]
|  | Diagnostic algorithm for children  | N/A | [ ]  |[ ]

|  |  |  |  |
| --- | --- | --- | --- |
| **Child and adolescent TB treatment**  | Regimens and dosages for treating TB (including CLHIV) | N/A | [ ]  |[ ]
|  | Monitoring, managing, and reporting adverse events for children and adolescents being treated for TB | N/A | [ ]  |[ ]
|  | Integration of TB treatment services with family and community-centered strategies | [ ]  | [ ]  |[ ]
| **Child and adolescent TB social factors** | Social protection mechanisms for children and adolescents diagnosed with TB | [ ]  | [ ]  |[ ]
|  | Strategies to combat stigma of children and adolescents diagnosed with TB | [ ]  | [ ]  |[ ]
|  | Child- and adolescent-centered care and adherence support for TB treatment and TPT (as well as caregivers) | [ ]  | [ ]  |[ ]
|  | Nutritional and other support for children and adolescents diagnosed with TB/DR-TB | N/A | [ ]  |[ ]
| **Child and adolescent TB/HIV** | Integration/alignment of TB and HIV care and treatment for children that are co-infected | [ ]  | [ ]  |[ ]

1*For example, the national strategic laboratory plan or national HIV guidelines.*